Head & Neck Cancer Network Site Specific Group. Clinical Guidelines. June 2015

Transcription

1 Somerset, Wiltshire, Avon and Gloucestershire (SWAG) Cancer Services Head & Neck Cancer Network Site Specific Group June 2015 Revision due: July 2015 Page 1 of 6

2 VERSION CONTROL THIS IS A CONTROLLED DOCUMENT. PLEASE DESTROY ALL PREVIOUS VERSIONS ON RECEIPT OF A NEW VERSION. Please check the SWSCN website for the latest version available here. VERSION DATE ISSUED SUMMARY OF CHANGE OWNER S NAME Draft 0.1 June 2015 First draft Page 2 of 6

3 This document was prepared by: Ceri Hughes, Chair of the SWAG Head and Neck, Consultant Maxillo-Facial Surgeon, University Hospitals NHS Foundation Trust Matthew Beasley, Consultant Clinical Oncologist, University Hospitals NHS Foundation Trust Helen Dunderdale, SWAG Cancer Network Support Manager These clinical guidelines have been agreed by: Name Position Trust Andrew Felstead Consultant Oral & Maxillofacial Surgeon R Consultant Oral & Maxillofacial Surgeon Steve Thomas Thomas Walker David Baldwin Graham Porter Consultant Oral & Maxillofacial Surgeon & Clinical Lecturer Consultant Ear, Nose, Throat, Head & Neck Surgeon Consultant Ear, Nose, Throat, Head & Neck Surgeon Stuart Gillett Consultant Ear, Nose, Throat, Head & Neck Surgeon R Charlie Hall Consultant Head & Neck & Thyroid Surgeon GLOS John Waldron Consultant Ear, Nose & Throat Surgeon R Paul Tierney Consultant Ear, Nose & Throat Surgeon Tony Robinson Consultant Ear, Nose & Throat Surgeon R Justin Morgan Consultant General & Transplant Surgeon NBT Richard Harris Consultant Ear, Nose & Throat Specialist Registrar Richard Sim Consultant Ear, Nose & Throat Specialist Registrar Miranda Flory Consultant Palliative Care Emma De Winton Consultant Clinical Oncologist Hoda Booz Consultant Clinical Oncologist Kate Allen Consultant Endocrinologist R Mimi Chen Consultant in Diabetes & Endocrinology R Auke Appelman Locum Consultant Neuroradiologist Date Agreed Page 3 of 6

4 Colette M Reid Consultant Palliative Medicine Paul Craig Consultant Histopathologist Glos Suzanne Hopcroft Consultant Histopathologist Glos Alica Torres Rendon Consultant Oral and Maxillofacial Pathologist Amanda Coles Consultant Pathologist Morwenna White- Thomson Consultant Pathologist Caroline Styles R Joya Pawade Consultant Pathologist Julian Kabala Mandy Williams Rebecca Davies Stewart Redman R Susan Armstrong Page 4 of 6

5 Head and Neck N Contents Section Contents Measures Page Introduction Upper Aero-digestive Tract (UAT) Cancer Thyroid Cancer (currently being updated) 14-1C-108i C-109i / 207i Introduction The following guidelines pertain to the local management of Head and Neck (H&N) malignancies for the Somerset, Wiltshire, Avon and Gloucestershire (SWAG) Network H&N Site Specific Group (N). The N refers to the Scottish Intercollegiate Guidelines for the Diagnosis and Management of Head and Neck Cancers (SIGN) and the British Association of Head and Neck Oncologists (BAHNO) guidelines. These local guidelines should be reviewed alongside three other key documents for the N: the Constitution, Annual Report and the Work Programme. The Constitution provides an overview of how the N operates, outlining the general working processes of the N, the patient referral pathways and the guidelines to which the N adheres. The Annual Report reflects the period of activity for the N from the previous year and it contains a summary of this activity measured against several key performance indicators that have been outlined in the National Cancer Peer Review Programme. The Work Programme summarises the key areas for growth, development and improvement of the N over the next financial year (and beyond where appropriate). All four documents should be reviewed together to give a full overview of the N, its performance and future plans. Primary care clinicians should refer to the NICE guidelines Suspected Cancer: recognition and management of suspected cancer in children, young people and adults (2015) for the signs and symptoms relevant when referring to Head and Neck services. Further details on the local process for referral can be found in the N constitution. The N is committed to offering all eligible patients entry into clinical trials where available. Consent to provide tissue for research purposes will also be sought wherever appropriate. Page 5 of 6

6 The N Agreed for Upper Aero-digestive Tract Cancer (measure14-1c-108i) The diagnosis, staging, treatment with surgery, radiotherapy and chemotherapy and the follow-up schedule for UAT cancers is performed as recommended by the SIGN and BAHNO guidelines. The N Agreed for Thyroid Cancer (14-1C-109i / 207i) Currently being updated -END- Page 6 of 6